716 research outputs found
Comment on "Novel Convective Instabilities in a Magnetic Fluid"
Comment on the paper "Novel Convective Instabilities in a Magnetic Fluid" by
W. Luo, T. Du, and J. Huang, Phys. Rev. Lett., v.82, p.4134 (1999).Comment: 1 page, 1 figure, To appear in Phys. Rev. Lett. (2001
Genetic Risk and Atrial Fibrillation in Patients with Heart Failure
Aims: To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure. Methods and results: An AF genetic risk score was calculated in 3759 European ancestry individuals (1783 with sinus rhythm, 1976 with AF) from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) by summing 97 single nucleotide polymorphism (SNP) alleles (ranging from 0â2) weighted by the natural logarithm of the relative SNP risk from the latest AF genome-wide association study. Further, we assessed AF risk variance explained by additive SNP variation, and performance of clinical or genetic risk factors, and the combination in classifying AF prevalence. AF was classified as AF or atrial flutter (AFL) at baseline electrocardiogram and/or a history of AF or AFL. The genetic risk score was associated with AF after multivariable adjustment. Odds ratio for AF prevalence per 1-unit increase genetic risk score was 2.12 (95% confidence interval 1.84â2.45, PÂ = 2.15 Ă 10â24) in the total cohort, 2.08 (1.72â2.50, PÂ = 1.30 Ă 10â14) in heart failure with reduced ejection fraction (HFrEF) and 2.02 (1.37â2.99, PÂ = 4.37 Ă 10â4) in heart failure with preserved ejection fraction (HFpEF). AF-associated loci explained 22.9% of overall AF SNP heritability. Addition of the genetic risk score to clinical risk factors increased the C-index by 2.2% to 0.721. Conclusions: The AF genetic risk score was associated with increased AF prevalence in HFrEF and HFpEF. Genetic variation accounted for 22.9% of overall AF SNP heritability. Addition of genetic risk to clinical risk improved model performance in classifying AF prevalence
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure
Aims
Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or nonâischaemic HF, it is important to better understand differences in underlying molecular mechanisms.
Methods and results
We performed a biological physical proteinâprotein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTATâCHF study, 715 of whom had ischaemic HF and 445 had nonâischaemic HF. Second, we constructed an enriched physical proteinâprotein interaction network, followed by a pathway overârepresentation analysis. Finally, we identified key network proteins. Data were validated in an independent HF cohort comprised of 765 ischaemic and 100 nonâischaemic HF patients. We found 21/92 proteins to be upâregulated and 2/92 downâregulated in ischaemic relative to nonâischaemic HF patients. An enriched network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key network proteins: acid phosphatase 5, epidermal growth factor receptor, insulinâlike growth factor binding proteinâ1, plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the independent validation cohort.
Conclusions
Pathophysiological pathways distinguishing patients with ischaemic HF from those with nonâischaemic HF were related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF
The Shapes of Flux Domains in the Intermediate State of Type-I Superconductors
In the intermediate state of a thin type-I superconductor magnetic flux
penetrates in a disordered set of highly branched and fingered macroscopic
domains. To understand these shapes, we study in detail a recently proposed
"current-loop" (CL) model that models the intermediate state as a collection of
tense current ribbons flowing along the superconducting-normal interfaces and
subject to the constraint of global flux conservation. The validity of this
model is tested through a detailed reanalysis of Landau's original conformal
mapping treatment of the laminar state, in which the superconductor-normal
interfaces are flared within the slab, and of a closely-related straight-lamina
model. A simplified dynamical model is described that elucidates the nature of
possible shape instabilities of flux stripes and stripe arrays, and numerical
studies of the highly nonlinear regime of those instabilities demonstrate
patterns like those seen experimentally. Of particular interest is the buckling
instability commonly seen in the intermediate state. The free-boundary approach
further allows for a calculation of the elastic properties of the laminar
state, which closely resembles that of smectic liquid crystals. We suggest
several new experiments to explore of flux domain shape instabilities,
including an Eckhaus instability induced by changing the out-of-plane magnetic
field, and an analog of the Helfrich-Hurault instability of smectics induced by
an in-plane field.Comment: 23 pages, 22 bitmapped postscript figures, RevTex 3.0, submitted to
Phys. Rev. B. Higher resolution figures may be obtained by contacting the
author
Linee guida ESC per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico 2008 = Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008
Determinants and clinical outcome of uptitration of ACE-inhibitor and beta-blocker in patients with heart failure:a prospective European study
Introduction:
Despite clear guidelines recommendations, most patients with heart failure and reduced ejectionâfraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that did not reach recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers (ARBs) and/or beta-blockers.
Methods and results:
BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors/ARBs and/or beta-blockers in 2516 heart failure patients from 69 centres in 11 European countries who were selected if they were suboptimally treated while initiation or uptitration was anticipated and encouraged. Patients who died during the uptitration period (nâ=â151) and patients with a LVEFâ>â40% (nâ=â242) were excluded. Median follow up was 21 months. We studied 2100 HFrEF patients (76% male; mean age 68â±12), of which 22% achieved the recommended treatment dose for ACE-inhibitor/ARB and 12% of beta-blocker. There were marked differences between European countries. Reachingâ<50% of the recommended ACE-inhibitor/ARB and beta-blocker dose was associated with an increased risk of death and/or heart failure hospitalization. Patients reaching 50â99% of the recommended ACE-inhibitor/ARB and/or beta-blocker dose had comparable risk of death and/or heart failure hospitalization to those reachingââ„100%. Patients not reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction had the highest mortality rate (for ACE-inhibitor/ARB: HR 1.72; 95% CI 1.43â2.01; for beta-blocker: HR 1.70; 95% CI 1.36â2.05).
Conclusion:
Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with patients reachingââ„100%
The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure
Background: CCL19 and CCL21, acting through CCR7, are termed homeostatic chemokines. Based on their role in concerting immunological responses and their proposed involvement in tissue remodeling, we hypothesized that these chemokines could play a pathogenic role in heart failure (HF). Methodology/Principal Findings: Our main findings were: (i) Serum levels of CCL19 and particularly CCL21 were markedly raised in patients with chronic HF (n = 150) as compared with healthy controls (n = 20). A CCL21 level above median was independently associated with all-cause mortality. (ii) In patients with HF following acute myocardial infarction (MI; n = 232), high versus low CCL21 levels 1 month post-MI were associated with cardiovascular mortality, even after adjustment for established risk factors. (iii). Explanted failing human LV tissue (n = 29) had markedly increased expression of CCL21 as compared with non-failing myocardium (n = 5). (iv) Our studies in CCR7â/â mice showed improved survival and attenuated increase in markers of myocardial dysfunction and wall stress in post-MI HF after 1 week, accompanied by increased myocardial expression of markers of regulatory T cells. (v) Six weeks post-MI, there was an increase in markers of myocardial dysfunction and wall stress in CCR7 deficient mice. Conclusions/Significance: High serum levels of CCL21 are independently associated with mortality in chronic and acute post-MI HF. Our findings in CCR7 deficient mice may suggest that CCL21 is not only a marker, but also a mediator of myocardial failure. However, while short term inhibition of CCR7 may be beneficial following MI, a total lack of CCR7 during long-term follow-up could be harmful.publishedVersio
Effects of comorbid anxiety disorders on the longitudinal course of pediatric bipolar disorders
OBJECTIVE: To examine the longitudinal effects of comorbid anxiety disorders in youth with bipolar spectrum disorder (BP). METHOD: As part of the Course and Outcome of Bipolar Youth study, 413 youth, who were 7 through 17 years or age and who met criteria for DSM-IV BP-I (n = 244), BP-II (n = 28), and operationally defined bipolar disorder not otherwise specified (BP-NOS) (n = 141) were included. Subjects were followed on average 5 years using the Longitudinal Interval Follow-up Evaluation. Effects of anxiety on the time to mood recovery and recurrence and percentage of time with syndromal and subsyndromal mood symptomatology during the follow-up period were analyzed. RESULTS: At intake and during the follow-up, 62% of youth with BP met criteria for at least 1 anxiety disorder. About 50% of the BP youth with anxiety had â„2 anxiety disorders. Compared to BP youth without anxiety, those with anxiety had significantly more depressive recurrences and significantly longer median time to recovery. The effects of anxiety on recovery disappeared when the severity of depression at intake was taken into account. After adjusting for confounding factors, BP youth with anxiety, particularly those with â„2 anxiety disorders, spent significantly less follow-up time asymptomatic and more time with syndromal mixed/cycling and subsyndromal depressive symptomatology compared to those without anxiety. CONCLUSIONS: Anxiety disorders are common and adversely affect the course of BP in youth, as characterized by more mood recurrences, longer time to recovery, less time euthymic, and more time in mixed/cycling and depressive episodes. Prompt recognition and the development of treatments for BP youth with anxiety are warranted
Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial
Cardiolog
Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure
Background Secretion of adrenomedullin (ADM) is stimulated by volume overload to maintain endothelial barrier function, and higher levels of biologically active (bio-) ADM in heart failure (HF) are a counteracting response to vascular leakage and tissue oedema. This study aimed to establish the value of plasma bio-ADM as a marker of congestion in patients with worsening HF. Methods and results The association of plasma bio-ADM with clinical markers of congestion, as well as its prognostic value was studied in 2179 patients with new-onset or worsening HF enrolled in BIOSTAT-CHF. Data were validated in a separate cohort of 1703 patients. Patients with higher plasma bio-ADM levels were older, had more severe HF and more signs and symptoms of congestion (all P <0.001). Amongst 20 biomarkers, bio-ADM was the strongest predictor of a clinical congestion score (r(2) = 0.198). In multivariable regression analysis, higher bio-ADM was associated with higher body mass index, more oedema, and higher fibroblast growth factor 23. In hierarchical cluster analysis, bio-ADM clustered with oedema, orthopnoea, rales, hepatomegaly and jugular venous pressure. Higher bio-ADM was independently associated with impaired up-titration of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers after 3 months, but not of beta-blockers. Higher bio-ADM levels were independently associated with an increased risk of all-cause mortality and HF hospitalization (hazard ratio 1.16, 95% confidence interval 1.06-1.27, P = 0.002, per log increase). Analyses in the validation cohort yielded comparable findings. Conclusions Plasma bio-ADM in patients with new-onset and worsening HF is associated with more severe HF and more oedema, orthopnoea, hepatomegaly and jugular venous pressure. We therefore postulate bio-ADM as a congestion marker, which might become useful to guide decongestive therapy
- âŠ